Evidence map›Paper›PMID 41639484›Full record

ArticleDoklady. Biochemistry and biophysics2026

Expression of Antioxidant Defense Genes Determines Synergistic Ferroptosis Induction by the Combination of Erastin and Omega-3 Docosahexaenoic Acid in Prostate Cancer Cells.

M O Silkina, T A Kulagin, K V Klycheva, A D Shatsillo, M D Mastykina, A V Razumovskaya, K M Nyushko, S V Nikulin

Abstract read
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

M O SilkinaNational Research University Higher School of Economics (HSE University), Moscow, Russia. mosilkina@hse.ru.
T A KulaginNational Research University Higher School of Economics (HSE University), Moscow, Russia.
K V KlychevaNational Research University Higher School of Economics (HSE University), Moscow, Russia.
A D ShatsilloNational Research University Higher School of Economics (HSE University), Moscow, Russia.
M D MastykinaNational Research University Higher School of Economics (HSE University), Moscow, Russia.
A V RazumovskayaNational Research University Higher School of Economics (HSE University), Moscow, Russia.
K M NyushkoLopatkin Research Institute of Urology and Interventional Radiology-Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Moscow, Russia.
S V NikulinNational Research University Higher School of Economics (HSE University), Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis is considered a promising strategy for inducing the death of tumor cells. However, the effectiveness of known ferroptosis inducers, such as erastin, is in some cases limited, which stimulates the search for new combined application strategies. In this study, the combined effect of erastin and docosahexaenoic acid (DHA) on prostate cancer cells was examined over time. It was shown that the combination of these agents is more toxic compared to their separate use for all tumor cells considered. At the same time, known ferroptosis inhibitors, ferrostatin-1 and deferoxamine, effectively prevented cell death, indicating the specificity of the mechanism of action. Transcriptomic analysis of cell lines differing in sensitivity to the combination revealed activation of antioxidant systems in more resistant cells (in particular, pronounced expression of the NQO1 and GCLM genes responsible for the reduction of quinones to hydroquinones and the synthesis of glutathione, respectively). The obtained results indicate the high synergistic potential of the erastin-DHA combination for ferroptosis induction and open new possibilities for the development of combined approaches to the therapy of resistant tumors.

Indexed as

AntioxidantsDocosahexaenoic AcidsFerroptosisGene Expression Regulation, NeoplasticPiperazinesProstatic NeoplasmsCell Line, TumorCyclohexylaminesDrug SynergismHumansMalePhenylenediaminesAntioxidantsCyclohexylaminesDocosahexaenoic AcidserastinPhenylenediaminesPiperazinesdocosahexaenoic aciderastinferroptosispolyunsaturated fatty acidsprostate cancer

Identifiers

PMID41639484
PMCPMC13167894

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.